Stephan Stilgenbauer, MD, University of Ulm, Ulm, Germany, discusses the current landscape of chemotherapy-free regimens for chronic lymphocytic leukemia (CLL). The introduction of more targeted oral agents, such as ibrutinib and venetoclax, has led to these agents being tested in upfront studies compared to chemoimmunotherapy. Several large randomized trials doing just this were presented at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.